Key Developments

In November 2022, Hexpol TPE, provider of flexible polymer materials, announced that it had launched medical mass balance thermoplastic elastomers. The new materials will form part of the Mediprene portfolio of TPEs for medical applications.
In March 2022, Eucure Biopharma, a wholly-owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trials of YH002 (anti-OX40 monoclonal antibody, mAb) in combination with YH001 (anti CTLA-4 mAb) in Australia.
In February 2022, Transcenta Holding Limited, a clinical biopharmaceutical company, announced the first patient dosed in phase IIa study of claudin 18.2 monoclonal antibody TST001 combined with cisplatin and gemcitabine for the first-line treatment of biliary tract cancer.
In October 2021, DuPont, a company engaged primarily in biotechnology and the manufacture of chemicals and pharmaceuticals, announced that it had inaugurated its new medical elastomers mixers at the Healthcare Industries Materials Site (HIMS) in Hemlock, Michigan, U.S.
In February 2020, PolyOne developed a new silicone-alternative TPE (thermoplastic elastomer), Versaflex HC BT218, for medical tubing. Versaflex HC BT218 adds to PolyOne’s broader portfolio of specialty engineered polymers for healthcare that meet stringent regulatory demands and are suitable for alternative sterilization methods, including gamma and autoclave.